Sanofi’s 2025 growth and 2026 outlook hinge on Dupixent and new launches

Transcript intelligence

What changed

The FY2025 analysis describes sales growth of 9.9% at constant exchange rates, with Dupixent and newer launches among the main drivers. Sanofi completed the Opella transaction and directed proceeds toward acquisitions and business development; it also plans increased U.S. manufacturing capacity and continued R&D investment. Compared with the prior-quarter analysis, the current picture emphasizes a full-year growth outlook and expanded pipeline and vaccine initiatives.

Guidance delta

Management maintained 2026 guidance for high single-digit sales growth, with business EPS expected to grow slightly faster than sales. The supplied analysis does not indicate a change to that outlook.

Key takeaways

• FY2025 sales grew 9.9% at constant exchange rates, according to the call analysis.
• Dupixent expansion and newer launches were identified as key growth drivers.
• Management’s 2026 outlook calls for high single-digit sales growth, with business EPS growing slightly faster.
• The strategy pairs pipeline advancement and U.S. capacity expansion with acquisitions and R&D investment.

Management priorities

• Expand Dupixent across additional indications and support new product launches.
• Advance late-stage pipeline programs, including amlitelimab, lunsekimig, itepekimab and TL1A.
• Complete and integrate the Dynavax acquisition and pursue selective early-stage opportunities.
• Expand U.S. manufacturing capacity and continue R&D and digital transformation investment.